前五月20余款1类新药获批 国内创新药上市跑出加速度

Core Insights - The Chinese innovative drug sector is experiencing rapid growth, with over 20 class 1 innovative drugs approved in the first five months of 2025, setting a record for the past five years [1][2] - The focus of these new drugs is primarily on oncology treatments, indicating a shift from "follow-up innovation" to "global leadership" in the pharmaceutical industry [1][3] Approval and Market Trends - In May 2025, the National Medical Products Administration approved 11 innovative drugs, including 7 class 1 drugs, highlighting a significant increase in approvals since 2020 [2] - The number of approved domestic class 1 innovative drugs has risen from single digits in 2018 and 2019 to over 30 in 2023 and 2024, with expectations to exceed 50 in 2025 [2][3] Policy Support and Innovation - Recent favorable policies have enhanced the innovation environment, covering all stages from research and evaluation to production and payment, thereby accelerating market access and shortening return cycles [4][5] - The implementation of a comprehensive support system for innovative drugs, including payment channel expansion and dynamic adjustments to the drug catalog, is expected to further stimulate research and development [5] International Competitiveness - China's biopharmaceutical research capabilities have significantly improved, with Chinese scholars ranking second globally in publications in top-tier journals [7] - At the ASCO annual meeting, over 70 original research results from China were presented, showcasing advancements in oncology and metabolic diseases [7] - The market confidence in domestic innovative drugs is reflected in the rapid growth of licensing agreements, with a total of $45.5 billion in license-out transactions reported in the first five months of 2025 [7][8]